BCL2 and cancer: The best example of the key role of non-coding RNAs in the development of new drugs for cancer treatment is provided by the venetoclax, a powerful, specific and well tolerated drug that compensates for the lack of miR-15a/miR-16-1 targeting of BCL2 in CLL.